Quinacrine sterilization (QS) in a private practice in Daytona Beach, Florida: a preliminary report.
OBJECTIVE
To affirm that QS can be performed safely and effectively in a U.S. private office practice.


METHODS
The U.S. FDA Modernization Act of 1997 Pharmacy Compounding Provisions made it possible for American physicians to begin offering QS to their patients. These provisions became effective November 21, 1998. This series was initiated in October 2000. The standard protocol recommended by the International Federation for Family Health (IFFH) is followed. Information on patients is recorded on forms suggested by IFFH to accomplish good post-marketing surveillance. The potential role of uterine septae in QS failures is of particular interest to this investigator.


RESULTS
Seven cases have been completed. There have been no failures. Side effects have been minor. Women have been exceptionally happy with this method. The Florida Agency for Health Care Administration has examined QS and found it to be an acceptable off-label use of quinacrine.


CONCLUSIONS
Preliminary results have been similar to those reported by QS researchers around the world.
Whitney
R B
RB
rwhitney3@cfl.rr.com
D000328:Adult; D004339:Drug Compounding; D004343:Drug Implants; D005260:Female; D005431:Florida; D005500:Follow-Up Studies; D006801:Humans; D007880:Legislation, Drug; D011331:Private Practice; D011796:Quinacrine / Q000008:administration & dosage*; D012102:Reproductive Control Agents / Q000008:administration & dosage*; D013246:Sterilization, Tubal / Q000331:legislation & jurisprudence / Q000379:methods*
D004343:Drug Implants; D012102:Reproductive Control Agents; D011796:Quinacrine